GRG's Center For Experiential Learning

Metastatic melanoma was once a near-certain death sentence, but PD-1/PD-L1 inhibitors have rewritten the story. From survival rates once measured in months to long-term remission and renewed hope, immune checkpoint therapies like nivolumab and pembrolizumab are transforming cancer care and reshaping the future of oncology.